BIOGEN IDEC - Data of BG-12 + Sales Growth Brighten 2012 Prospects
Biogen Idec (BIIB) is closing 2011 with a positive note and promise to deliver more in 2012! BIIB revised its FY11 financial guidance, expecting revenue growth to be in the mid-single digits – towards higher end of its prior guidance of low to mid-single digit growth based on the robust earnings. Positive top line data of BG-12 (PhIII, RRMS) in a head-to-head PhIII trial vs. Copaxone in CONFIRM reaffirmed the efficacy and safety seen in DEFINE (PhIII trial) threatening Teva’s Copaxone (L, RRMS) share of the MS market. Moreover, PhIIb data readouts from SELECT trial of Daclizumab HYP (PhII, IL-2 alpha subunit mAb, SC, partnered with Abbott Lab) showed good efficacy – reduced ARR by 50% compared to placebo. However, the safety… For more details, please read our report, released on Nov. 8, 2011 on “Biogen Idec - Data of BG-12 + Sales Growth Brighten 2012 Prospects”
COMPANIES MENTIONED
BIOGEN IDEC
BIOGEN IDEC
